## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%); PEG 1.56 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($34.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Why Myriad Genetics (MYGN) Stock Is Trading Lower Today**
- Source: Finviz | 20251201T123600 | Somewhat-Bullish | Relevance: 67%
-  Shares of Myriad Genetics (NASDAQ:MYGN) fell 6% after the FDA approved a competing blood-based prostate cancer test from Cleveland Diagnostics, IsoPSA. This new diagnostic kit increases competition in the prostate cancer market, raising investor concerns about Myriad's market share. Investors reacted negatively to the news, signaling increased competition in cancer diagnostics.

**2. Brown & Brown Employer Health and Benefits Strategy Survey | 2026 Edition**
- Source: Brown & Brown | 20251201T190628 | Neutral | Relevance: 63%
- Brown & Brown's second annual Employer Health and Benefits Strategy Survey for 2026 highlights rising costs, evolving workforce needs, and a focus on innovation and sustainability as key shapers of the benefits landscape. The survey, which included 1,241 employers, found a shift in strategic priorities, with cost control now topping the list for both employees and employers. Attracting and retaining a healthy and engaged workforce, previously the top priority, moved to third place.

**3. Moderna (MRNA) Leads Healthcare Gains with 16.19% Surge**
- Source: GuruFocus | 20251130T085500 | Somewhat-Bullish | Relevance: 62%
- Moderna (MRNA) surged 16.19% last week, leading the S&P 500 healthcare sector amidst a broader market rally. Despite strong liquidity and low debt, the company faces significant challenges with negative revenue growth and profitability, indicated by a low Piotroski F-Score and mid-range Altman Z-Score. Its valuation shows mixed signals with a neutral RSI-14 and a GF Score of 55, classifying it as a distressed stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 15.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.56 elevated, pricing in significant growth expectations. Forward P/E 13.0x attractive for 46% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.0B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.56 |
| Forward P/E | 13.0 |
| Current P/E | 19.0 |
| YoY Growth | 46.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 4.5% to -1.3% (-5.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.85x), long-term trend not supportive. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.29% (CS: 39) | Neutral |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 0.846x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $37.89
- **Stop Loss:** $34.67 (8.5% risk)
- **Target:** $41.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 232
- **Position Value:** $8,790.48
- **Portfolio %:** 8.79%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*